Gonadotropin-Releasing Hormone Antagonists Revolutionizing Gynecology
- PMID: 36357969
- DOI: 10.1097/AOG.0000000000005012
Gonadotropin-Releasing Hormone Antagonists Revolutionizing Gynecology
Conflict of interest statement
Financial Disclosure Hugh S. Taylor received grant support from AbbVie to Yale University to support Dr. Taylor's research. Ecem Esencan did not report any potential conflicts of interest.
Comment on
-
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.Obstet Gynecol. 2022 Dec 1;140(6):920-930. doi: 10.1097/AOG.0000000000004988. Epub 2022 Nov 2. Obstet Gynecol. 2022. PMID: 36357960 Free PMC article. Clinical Trial.
References
-
- Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino WH. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. J Assist Reprod Genet 2012;29:703–12. doi: 10.1007/s10815-012-9784-0 - DOI
-
- Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100–7. doi: 10.1067/mob.2003.99 - DOI
-
- Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012;206:211.e1–9. doi: 10.1016/j.ajog.2011.12.002 - DOI
-
- Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344–55. doi: 10.1056/NEJMra1209993 - DOI
-
- Al-Hendy A, Lukes AS, Poindexter A, Venturella R, Villarroel C, McKain L, et al. Long-term relugolix combination therapy for symptomatic uterine leiomyomas. Obstet Gynecol 2022:140:920–30. doi: 10.1097/AOG.0000000000004988 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources